Redesigning oncology clinical trials with agentic AI
Redesigning oncology clinical trials with agentic AI
https://dailyreporter.esmo.org/homepage/opinion/redesigning-oncology-clinical-trials-with-agentic-ai
Publish Date: 2026-03-18 05:05:00
Source Domain: dailyreporter.esmo.org
- AI’s Growing Role in Cancer Research: AI technologies are rapidly transforming the oncology research landscape, with current AI models performing varied tasks in semi-autonomous methods at high precision and accuracy.
- Large-Scale Foundation Model: A collaboration among a pharmaceutical company and AI firms produced the largest multimodal foundation model in oncology, integrating various patient data sources to improve treatment research.
- Predictive and Efficient Drug Development: AI models facilitate the prediction of treatment responses, speeding up the development and combination of novel and existing therapies, while also streamlining clinical trials and regulatory processes.
- Predictive Biomarkers and Rapid Development: The introduction of new predictive biomarkers, such as the antibody–drug conjugate for non-small cell lung cancer, showcases how AI accelerates biomarker development and reduces traditional development timelines.
- Ecosystem of Collaboration: Successful oncology AI research relies on partnerships between pharmaceutical companies, AI specialists, academic institutions, and patient advocacy groups, leveraging domain-specific AI models and patient insights.
- Accelerated Drug Discovery: AI’s ability to generalize on small datasets accelerates the discovery of new treatments, reducing time, workforce, and cost, and enhancing early cancer detection and toxicity prediction.
- Present and Future of AI in Healthcare: AI tools are already integral to oncology R&D and their incorporation is set to significantly enhance the speed and efficiency of personalized care delivery.
